{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:40:21Z","timestamp":1789782021211,"version":"4.0.1"},"reference-count":87,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100013278","name":"JPND","doi-asserted-by":"crossref","award":["JPND2019 466-236"],"award-info":[{"award-number":["JPND2019 466-236"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["NRC 311993"],"award-info":[{"award-number":["NRC 311993"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007137","name":"Helse Nord RHF","doi-asserted-by":"publisher","award":["HNF1540-20"],"award-info":[{"award-number":["HNF1540-20"]}],"id":[{"id":"10.13039\/501100007137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-03393"],"award-info":[{"award-number":["2019-03393"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005989","name":"Ministrstvo za Izobra\u017eevanje, Znanost in \u0160port","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100005989","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005989","name":"Ministrstvo za Izobra\u017eevanje, Znanost in \u0160port","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100005989","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005989","name":"Ministrstvo za Izobra\u017eevanje, Znanost in \u0160port","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100005989","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005989","name":"Ministrstvo za Izobra\u017eevanje, Znanost in \u0160port","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/501100005989","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The introduction of anti-amyloid treatments (AAT) for Alzheimer's disease (AD) has put the cost-effectiveness into focus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Estimate the potential cost-effectiveness of diagnostic pathways combined with AAT for early AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Diagnostic accuracy of blood-based (BBM) and cerebrospinal fluid (CSF) biomarkers was obtained from Norwegian memory clinics using positron emission tomography (PET) as reference standard. In a health-economic model, the cost-effectiveness of three diagnostic strategies was estimated relying either on BBM (p-tau 217), CSF (A\u03b2\n                      <jats:sub>42\/40<\/jats:sub>\n                      ratio), and BBM with CSF confirmatory testing and compared with standard of care (SoC) and compared with CSF-AAT. The model consisted of a decision tree reflecting the diagnostic process and a subsequent Markov cohort model starting at mild cognitive impairment due to AD. All strategies except SoC were combined with AAT including costs of treatment (assumed \u20ac5000\/year), infusions and monitoring.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with SoC all three strategies (CSF-AAT, BBM-AAT, and BBM-CSF-AAT) resulted in QALY gains at higher costs, with an incremental cost-effectiveness ratio (ICER) of 110k\u20ac, 141k\u20ac and 110k\u20ac respectively. Compared with CSF-AAT both BBM-AAT and BBM-CSF-AAT strategies resulted in QALYs lost at lower costs, with an ICER of 27k\u20ac and 109k\u20ac respectively. Results were particularly sensitive to the price of AAT and possible subcutaneous administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with SoC all three strategies are potentially not cost-effective as they exceeded the Swedish maximum willingness to pay threshold of \u20ac94,800 per QALY gained. BBM-CSF-AAT versus CSF-AAT is potentially cost-effective if willing to accept its QALY loss. Discussions on budget impact on different payers are needed after introducing AAT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877251323231","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:15:04Z","timestamp":1742490904000},"page":"1167-1184","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting"],"prefix":"10.1177","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0963-5750","authenticated-orcid":false,"given":"Anders","family":"Wimo","sequence":"first","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, BioClinicum J9:20, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8663-0630","authenticated-orcid":false,"given":"Ron","family":"Handels","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, BioClinicum J9:20, Karolinska Institutet, Solna, Sweden"},{"name":"Maastricht University, Alzheimer Centre Limburg, Faculty of Health, Medicine and Life Sciences, Maastricht, Netherlands"},{"name":"Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1413-9578","authenticated-orcid":false,"given":"Bj\u00f8rn-Eivind","family":"Kirsebom","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital of North Norway, Troms\u00f8, Norway"},{"name":"Department of Psychology, Faculty of Health Sciences, The Arctic University of Norway, Troms\u00f8, Norway"},{"name":"Department of Neurology, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5131-9757","authenticated-orcid":false,"given":"Per","family":"Selnes","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Research, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0256-8640","authenticated-orcid":false,"given":"Jaka","family":"Bon","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8229-2706","authenticated-orcid":false,"given":"Andreja","family":"Emersic","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia"},{"name":"Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-9456","authenticated-orcid":false,"given":"Fernando","family":"Gonzalez-Ortiz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8231-1176","authenticated-orcid":false,"given":"Milica","family":"Gregoric Kramberger","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia"},{"name":"Medical Faculty, University of Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-2248","authenticated-orcid":false,"given":"Anders","family":"Sk\u00f6ldunger","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, BioClinicum J9:20, Karolinska Institutet, Solna, Sweden"},{"name":"Department of Nursing, Biologihuset, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1300-6730","authenticated-orcid":false,"given":"Andreja","family":"Speh","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3652-1820","authenticated-orcid":false,"given":"Santiago","family":"Tim\u00f3n-Reina","sequence":"additional","affiliation":[{"name":"Department of Neurology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7774-5500","authenticated-orcid":false,"given":"Ellen","family":"Vromen","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vumc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8008-9727","authenticated-orcid":false,"given":"Pieter","family":"Jelle Visser","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vumc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands"},{"name":"Department of Psychiatry, Maastricht University, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-1179","authenticated-orcid":false,"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, BioClinicum J9:20, Karolinska Institutet, Solna, Sweden"},{"name":"Karolinska University Hospital, Theme Inflammation and Aging, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9984-9797","authenticated-orcid":false,"given":"Tormod","family":"Fladby","sequence":"additional","affiliation":[{"name":"Department of Neurology, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"e_1_3_5_2_2","volume-title":"Global status report on the public health response to dementia","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Global status report on the public health response to dementia. Geneva: World Health Organization, 2021."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00062-4"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv181"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.1323"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.004"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02988-7"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.141"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01484-7"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00128-X"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00176-X"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.3770"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_5_19_2","unstructured":"GOV.UK. Lecanemab licensed for adult patients in the early stages of Alzheimer\u2019s disease https:\/\/www.gov.uk\/government\/news\/lecanemab-licensed-for-adult-patients-in-the-early-stages-of-alzheimers-disease (2024 accessed Aug 26 2024 2024)."},{"key":"e_1_3_5_20_2","unstructured":"GOV.UK. Donanemab licensed for early stages of Alzheimer\u2019s disease in adult patients who have one or no copies of apolipoprotein E4 gene https:\/\/www.gov.uk\/government\/news\/donanemab-licensed-for-early-stages-of-alzheimers-disease-in-adult-patients-who-have-one-or-no-copies-of-apolipoprotein-e4-gene (2024 accessed Oct 23 2024 2024)."},{"key":"e_1_3_5_21_2","unstructured":"NICE. Benefits of new Alzheimer\u2019s treatment lecanemab are too small to justify the cost to the NHS https:\/\/www.nice.org.uk\/news\/articles\/benefits-of-new-alzheimer-s-treatment-lecanemab-are-too-small-to-justify-the-cost-to-the-nhs (2024 accessed Aug 26 2024 2024)."},{"key":"e_1_3_5_22_2","unstructured":"EMA. Leqembi recommended for treatment of early Alzheimer\u2019s disease https:\/\/www.ema.europa.eu\/en\/news\/leqembi-recommended-treatment-early-alzheimers-disease (2024 accessed Nov 14 2024 2024)."},{"key":"e_1_3_5_23_2","article-title":"Lecanemab for Alzheimer's disease","volume":"379","author":"Walsh S","year":"2022","unstructured":"Walsh S, Merrick R, Richard E, et al. Lecanemab for Alzheimer's disease. BMJ 2022; 379: o3010.","journal-title":"BMJ"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01129-x"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1370\/afm.3050"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.44"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100657"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.112"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.17925\/USN.2023.19.1.14"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.05.017"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00403-3"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.68"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-00942-2"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-00977-5"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.02.005"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610218001291"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-024-00878-0"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-018-0192-8"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.02.009"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-017-0054-z"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.23"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209218"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.67"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X18797590"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac244"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1848551"},{"key":"e_1_3_5_47_2","volume-title":"Precision medicine interventions in Alzheimer\u2019s disease","author":"Fladby T","year":"2019","unstructured":"Fladby T. Precision medicine interventions in Alzheimer\u2019s disease. Research plan. Oslo: Department of Neurology, Akershus University Hospital, 2019."},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170231"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.6126"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99794-9"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.2174\/1567205011310020011"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-191055"},{"key":"e_1_3_5_54_2","article-title":"New international pharmaco-economic collaboration on Alzheimer's disease (IPECAD) open-source model framework for the health technology assessment of early Alzheimer's disease treatment: Development and use cases","author":"Handels R","unstructured":"Handels R, Herring WL, Grimm S, et al. New international pharmaco-economic collaboration on Alzheimer's disease (IPECAD) open-source model framework for the health technology assessment of early Alzheimer's disease treatment: Development and use cases. Value Health. Epub ahead of print 31 July 2024. DOI: https:\/\/doi.org\/10.1016\/j.jval.2024.07.009.","journal-title":"Value Health"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116538"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv029"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610204000092"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2828"},{"key":"e_1_3_5_59_2","volume-title":"Demenssjukdomarnas samh\u00e4llskostnader i Sverige 2919","author":"Frisell O","year":"2023","unstructured":"Frisell O, J\u00f6nsson L, Wimo A. Demenssjukdomarnas samh\u00e4llskostnader i Sverige 2919. Stockholm: Karolinska Institutet, 2023."},{"key":"e_1_3_5_60_2","volume-title":"Demensf\u00f6rekomst i Sverige: geografiska och tidsm\u00e4ssiga trender 2001-2013. Resultat fr\u00e5n den svenska nationella studien om \u00e5ldrande, v\u00e5rd och omsorg - SNAC","author":"Fratiglioni L","year":"2018","unstructured":"Fratiglioni L, Ding M, Santoni G, et al. Demensf\u00f6rekomst i Sverige: geografiska och tidsm\u00e4ssiga trender 2001-2013. Resultat fr\u00e5n den svenska nationella studien om \u00e5ldrande, v\u00e5rd och omsorg - SNAC. Stockholm: Aging Research Center, 2018."},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-016-0747-5"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.05.004"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1725"},{"key":"e_1_3_5_64_2","article-title":"Preliminary update on lecanemab safety in clarity AD open-label extension, including subcutaneous formulation","volume":"10","author":"Irizarry M","year":"2023","unstructured":"Irizarry M, Li D, Dhadda S, et al. Preliminary update on lecanemab safety in clarity AD open-label extension, including subcutaneous formulation. J Prev Alzheimers Dis 2023; 10: S10\u2013S11.","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_3_5_65_2","volume-title":"Eisai initiates rolling biologics license application to US FDA for LEQEMBI\u00ae (lecanemab-irmb) for subcutaneous maintenance dosing for the treatment of early Alzheimer\u2019s disease under the fast track status","author":"Biogen","year":"2024","unstructured":"Biogen. Eisai initiates rolling biologics license application to US FDA for LEQEMBI\u00ae (lecanemab-irmb) for subcutaneous maintenance dosing for the treatment of early Alzheimer\u2019s disease under the fast track status. Cambridge US and Tokyo, Japan: Biogen and Eisai, 2024."},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10729-022-09608-1"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13044"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2282020915"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170324"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.13855"},{"key":"e_1_3_5_71_2","unstructured":"Global E. Eisai\u2019s approach to U.S. pricing for Leqembi\u2122 (lecanemab) a treatment for early Alzheimer\u2019s disease sets forth our concept of \u201csocietal value of medicine\u201d in relation to \u201cprice of medicine\u201d https:\/\/www.eisai.com\/news\/2023\/news202302.html (2023 accessed 17 Nov 2023 2023)."},{"key":"e_1_3_5_72_2","unstructured":"ICER. ICER Publishes Evidence Report on Lecanemab for Alzheimer\u2019s Disease ttps:\/\/icer.org\/news-insights\/press-releases\/icer-publishes-evidence-report-on-lecanemab-for-alzheimers-disease\/ (2023 accessed May 5 2023)."},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0315"},{"key":"e_1_3_5_74_2","unstructured":"JapanTimes. New Alzheimer's drug to be covered by health insurance in Japan https:\/\/www.japantimes.co.jp\/news\/2023\/12\/13\/japan\/eisai-biogen-alzheimers-drug-price\/ (2023 accessed June 17 2024)."},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12811"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12694"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201043"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002254"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.009"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12960-023-00842-4"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.7249\/RR2503"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-210303"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13759"},{"key":"e_1_3_5_86_2","article-title":"Towards implementation of plasma phospho-tau 181 as a screening tool for patient recruitment","volume":"9","author":"Emer\u0161i\u010d A","year":"2022","unstructured":"Emer\u0161i\u010d A, Kirsebom BE, Brum WS, et al. Towards implementation of plasma phospho-tau 181 as a screening tool for patient recruitment. J Prev Alzheimers Dis 2022; 9: S174.","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2020.1822738"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14108"},{"key":"e_1_3_5_89_2","article-title":"Donanemab: conflicts of interest found in FDA committee that approved new Alzheimer's drug","volume":"386","author":"Lenzer J","year":"2024","unstructured":"Lenzer J, Brownlee S. Donanemab: conflicts of interest found in FDA committee that approved new Alzheimer's drug. BMJ 2024; 386: q2010.","journal-title":"BMJ"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251323231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251323231","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251323231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:10:07Z","timestamp":1777371007000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251323231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/13872877251323231"],"URL":"https:\/\/doi.org\/10.1177\/13872877251323231","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}